Literature DB >> 18406498

[Vitamin D2 or vitamin D3?].

V I Mistretta1, P Delanaye, J-P Chapelle, J-C Souberbielle, E Cavalier.   

Abstract

PURPOSE: Nearly one billion people around the world are deficient in vitamin D and need to be supplemented. Vitamin D is available in medicines and fortified foods. It is available in two forms: vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol). KEY POINTS: The pharmacopeiae consider these steroid hormones as equivalent and interchangeable. However, several studies have showed that serum level of 25(OH)D is increased more effectively with vitamin D3 than vitamin D2. Vitamin D2 has shorter plasma half-life and a lower affinity for the vitamin D binding protein, the hepatic vitamin D hydroxylase and the vitamin D receptor.
CONCLUSION: Vitamin D2 should not be regarded anymore as suitable for supplementation or fortification. Currently though, it is still the most used in some countries such as Portugal and Australia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18406498     DOI: 10.1016/j.revmed.2008.03.003

Source DB:  PubMed          Journal:  Rev Med Interne        ISSN: 0248-8663            Impact factor:   0.728


  3 in total

Review 1.  A dermatologist's perspective on vitamin D.

Authors:  Veena Vanchinathan; Henry W Lim
Journal:  Mayo Clin Proc       Date:  2012-03-14       Impact factor: 7.616

Review 2.  Vitamin D supplementation in older adults: searching for specific guidelines in nursing homes.

Authors:  Y Rolland; P de Souto Barreto; G Abellan Van Kan; C Annweiler; O Beauchet; H Bischoff-Ferrari; G Berrut; H Blain; M Bonnefoy; M Cesari; G Duque; M Ferry; O Guerin; O Hanon; B Lesourd; J Morley; A Raynaud-Simon; G Ruault; J-C Souberbielle; B Vellas
Journal:  J Nutr Health Aging       Date:  2013-04       Impact factor: 4.075

3.  A Randomised, Double-Blinded, Placebo-Controlled, Parallel Study of Vitamin D3 Supplementation with Different Schemes Based on Multiples of 25,000 IU Doses.

Authors:  Etienne Cavalier; Werner Faché; Jean-Claude Souberbielle
Journal:  Int J Endocrinol       Date:  2013-01-28       Impact factor: 3.257

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.